GluSense

Diabetes type I patients and other insulin-dependent patients are required to monitor their blood glucose levels many times every day in order to manage their condition. Most patients currently use glucose meters which require to pierce the finger in order to draw blood, which not only is painful, but missing trend information which is important for best treatment. Continuous glucose monitoring devices which currently make a small part of the market are not providing sufficiently accurate measurements, require calibration to blood measurements several times a day and last only a few days.\GluSense is developing a innovative solution for Diabetes Type I patients – a miniature, injectable device which will provide accurate, continuous glucose measurements over a period of over 6 months. \GluSense technology is based on a fluorescent protein which reports the level of glucose. Long term operation is achieved using engineered live cells which are encapsulated within the device and continuously produce the fluorescent protein. \Following extensive technology development and successful feasibility tests, done in the earlier years of the company, the company is now in advanced stages of product development. Multiple successful animal tests have been performed and a first-in-human clinical study is planned for 2018.\For more information – see our new website at http://www.glusensemedical.com\For additional info please contact: Boaz Brill, CEO at : [email protected]

Company’s Keywords:

continuous glucose monitoring diabetes, continuous glucose monitoring, diabetes